Full-text resources of CEJSH and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

Refine search results

Journals help

  1. 2 Gabinet Prywatny

Authors help

  1. 1 Pęksa J.

  2. 1 Pęksa J. W.

Years help

  1. 2 2022

Results found: 2

first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  ezetimibe
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Połączenie atorwastatyny i ezetymibu w terapii hipercholesterolemii

100%
Pęksa J.
Gabinet Prywatny
|
2022
|
vol. 29 (282)
|
issue 03
5-13
EN
Cardiovascular (CV) diseases are still the leading cause of death in Poland. In treatment of hypercholesterolemia, HMG-CoA reductase inhibitors (statins) are the first-line drugs with proven beneficial effect on patient prognosis. These drugs include one of the two potent statins, atorvastatin. If the target level of LDL cholesterol is not achieved despite lifestyle changes and statin therapy, a drug with a different mechanism of action, e.g. ezetimibe, is added to the treatment. In this way a greater hypolipemic effect is achieved. Single pill combinations (SPC) containing two active substances in one tablet are a good choice. Indications for therapy with SPC preparations with statins and ezetimibe include therapy for primary hypercholesterolemia, mixed hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, and prevention of CV events in patients at increased risk for these incidents. SPC drug is used to control hypercholesterolemia with atorvastatin and ezetimibe as separate formulations, at the same doses as in the combination formulation. SPC formulations containing 10 mg of ezetimibe in combination with 10 or, 20, or 40 or 80 mg of atorvastatin are available on the Polish pharmaceutical market.
2
Publication available in full text mode
Content available

Atorwastatyna i ezetymib – skuteczne połączenie w terapii dyslipidemii

100%
Pęksa J. W.
Gabinet Prywatny
|
2022
|
vol. 284
|
issue 04
7-12
EN
A good therapeutic option in hypercholesterolemia is the use of combination preparations containing an HMG-CoA reductase inhibitor, such as atorvastatin, and a drug that selectively inhibits the absorption of holesterol and plant sterol derivatives from the gut - ezetimibe - in a single tablet. Such treatment can be implemented in adults with primary hypercholesterolemia, familial hypercholesterolemia or mixed hyperlipidemia, which is already controlled with atorvastatin and ezetimibe as separate preparations, at the same doses as in the combination preparation. The preparation is administered 1x /day at any time, day. It is mostly a safe drug and well tolerated by patients. Possible side effects are mainly due to possible side effects of statins.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.